Navigation Links
Omeros to Present at Two Upcoming Conferences
Date:8/3/2011

SEATTLE, Aug. 3, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences:

2011 Canaccord Genuity Growth Conference
August 10, 2011
9:00 a.m. EDT
Boston, MA

Wedbush 2011 Life Sciences Management Access Conference
August 17, 2011
8:35 a.m. EDT
New York, NY

The presentations will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Omeros to Present at Future Leaders in the Biotech Industry Conference
2. Omeros to Present at Needham Healthcare Conference
3. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
4. Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
5. Omeros Secures $40 Million Committed Equity Financing Facility
6. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
7. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
8. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
9. Omeros Commences Initial Public Offering of Common Stock
10. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
11. Omeros Appoints New Vice President of Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Neogen Corporation (NASDAQ: ... terminated its agreement with SenesTech Incorporated (NASDAQ: ... a rodenticide being developed by SenesTech. The two firms ... time when the SenesTech product was approved by the ... approval provided that the product could only be used ...
(Date:1/24/2017)... and DURHAM, N.C. , ... IRB in customer service and technology, announces that ... the organization as Biosafety Officer. In ... leadership to develop and manage a forthcoming institutional biosafety ... for research organizations navigating the IBC landscape. The new ...
(Date:1/24/2017)... Calif. , Jan. 24, 2017  Asterias ... pioneering the field of regenerative medicine, today announced ... Phase 1/2a clinical trial that showed additional motor ... of 10 million AST-OPC1 cells in AIS-A patients ... "Recovery of upper extremity motor function is ...
(Date:1/24/2017)... New York, NY (PRWEB) , ... January 24, ... ... index (BMI), larger waist circumference, and increased serum leptin levels had a positive ... study. The study published in the International Neurourology Journal involved ...
Breaking Biology Technology:
(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):